Skip to main content
Log in

β-Lactamases in Clinical Isolates Spectrum Implications of Sulbactam/Ampicillin

  • Problems of Resistance in clinical Infection
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Combining ampicillin with an irreversible β- lactamase inhibitor such as sulbactam is a promising technique for controlling infections due to resistant organisms. The combination not only restores the effectiveness of ampicillin against species that have acquired resistance to it, but it can extend the antimicrobial spectrum to species that have never exhibited susceptibility to ampicillin.

However, the inhibition of β- lactamases and the evaluation of inhibitors are still complicated by numerous factors known collectively as ‘the epidemiology of β- lactamases’. This refers to the distribution of enzymes in different bacterial species and in different geographical locations, the numerous types of enzymes, the variable number and amount of β- lactamases that may exist in the same cell, and, of course, the potential for transfer of β- lactamase resistance from one species to another.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Acar JF, Minozzi C. Role of β-laclamases in the resistance of gram-negative bacilli to β-lactam antibiotics. Review of Infectious Diseases 8 (Suppl. 5): S482–S486. 1986

    Article  CAS  Google Scholar 

  • Arisawa M. Then RL. 6 Acetylmethylene-penicillanic acid (Ro 15-1903), a potent β-laclamase inhibitor. I. Inhibition of chromosomally and R-factor mediated β-lactamases. Journal of Antibiotics 35: 1578–1583. 1982

    Article  PubMed  CAS  Google Scholar 

  • Bush K. Sykes RB. β-Lactamase inhibitors in perspective. Journal of Antimicrobial Chemotherapy 11: 97–107. 1983

    Article  PubMed  CAS  Google Scholar 

  • Eley A, Greenwod D. Characterization of β-lactamases in clinical isolates of bacteroides. Journal of Antimicrobial Chemotherapy 18: 325–333, 1986

    Article  PubMed  CAS  Google Scholar 

  • Kitzis MD, Goldstein FW, Labia R. Acar JF. Activité du sulbactam et de l’acide clavulanique, seuls ou associés, sur Acinelobacter calcoaceticus. Annals of Microbiology (Institut Pasteur) 134A: 163–168, 1983

    Article  CAS  Google Scholar 

  • Medeiros AA. β-Lactamases. British Medical Bulletin 40: 18–27, 1984

    PubMed  CAS  Google Scholar 

  • Philippon A. Paul G. Nevot P. Mécanisme de résistance enzymatique aux β-laclamines. Presse Médicale 46: 2290–2296. 1986

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Acar, J.F., Gutmann, L. & Kitzis, MD. β-Lactamases in Clinical Isolates Spectrum Implications of Sulbactam/Ampicillin. Drugs 35 (Suppl 7), 12–16 (1988). https://doi.org/10.2165/00003495-198800357-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-198800357-00004

Keywords

Navigation